Compare ACOG & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACOG | INO |
|---|---|---|
| Founded | 2000 | 1979 |
| Country | Canada | United States |
| Employees | 57 | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.4M | 90.5M |
| IPO Year | N/A | 1999 |
| Metric | ACOG | INO |
|---|---|---|
| Price | $7.00 | $1.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $16.00 | $6.75 |
| AVG Volume (30 Days) | 30.0K | ★ 1.6M |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $42,220,086.00 |
| Revenue This Year | $139.22 | $20,156.19 |
| Revenue Next Year | $134.48 | $421.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.37 |
| 52 Week Low | $4.50 | $1.03 |
| 52 Week High | $10.88 | $2.86 |
| Indicator | ACOG | INO |
|---|---|---|
| Relative Strength Index (RSI) | 68.32 | 41.74 |
| Support Level | $6.46 | $1.03 |
| Resistance Level | $7.69 | $1.23 |
| Average True Range (ATR) | 0.36 | 0.06 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 91.89 | 22.92 |
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.